{"ticker": {"uuid": "f62fe625-a47c-4807-b40e-0314b110928a", "symbol": "BRNS", "name": "Barinthus Biotherapeutics plc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Barinthus Biotherapeutics (NasdaqCM:BRNS) Stock Price", "summary": "Barinthus Biotherapeutics (NasdaqCM:BRNS) has a market cap of US$26.1m and its stock price recently decreased by 36.22% over seven days. The company, founded in 2016, focuses on immunotherapies and vaccines, with candidates in clinical trials for celiac disease and chronic hepati", "url": "https://simplywall.st/stock/nasdaqcm/brns", "source_name": "Simply Wall Street", "published_at": "2026-07-05T01:10:43", "published_display": "05 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) wins more time to meet Nasdaq $1 bid rule", "summary": "Barinthus Biotherapeutics (BRNS) has been granted an additional 180 days, until December 28, 2026, by Nasdaq to regain compliance with the minimum $1.00 per share bid price requirement. In connection with this extension, its American Depositary Shares were transferred from the Na", "url": "https://www.stocktitan.net/sec-filings/BRNS/8-k-barinthus-biotherapeutics-plc-reports-material-event-b15c9c7d56b7.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:54", "published_display": "02 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) Sinks Further as Shares Test Critical Support Near $0.58 - Flat Correction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTUtHMTQtZ2J3alhFcVU0bENIY09iQjBkeHJEc0VQbTYwQTNDcGd4d0ppUUZVS2J2MnNnSXRyQy1xNjdXZlczRDdqeE0zc1N1M1F3aVRfQzRybXVaY3g2TEV2V1VLMGktUXlGRm1uZENsZDlCVjlxSllYNWtrcnA1NjZtTUlHWVVkeDBfWVc3d1BnTWlQZl9PRUJLOW8ySF8zRl9VMjlZcDZ6MnY0cm1sTXB2ckRrbHJIU2VUSldRMVY?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-02T16:33:41+00:00", "published_display": "02 Jul 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Barinthus Biotherapeutics plc \u2013 NASDAQ:BRNS", "summary": "This article provides the \"Price to book forward\" value for Barinthus Biotherapeutics plc (NASDAQ: BRNS) within the context of a financial data platform. It shows the company's stock market information and indicates that the market is currently closed with no trades. The article ", "url": "https://www.tradingview.com/symbols/NASDAQ-BRNS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T15:10:42", "published_display": "27 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Barinthus Biotherapeutics plc \u2013 NASDAQ:BRNS", "summary": "This article provides the \"Price to earnings forward\" financial data for Barinthus Biotherapeutics plc (NASDAQ:BRNS). It appears to be a direct data output from a financial platform, showing the value and change percentages for this specific metric, though the values themselves a", "url": "https://www.tradingview.com/symbols/NASDAQ-BRNS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:27", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Barinthus Biotherapeutics plc Sponsored ADR \u2013 DUS:2AB", "summary": "This page from TradingView provides financial information for Barinthus Biotherapeutics plc Sponsored ADR (DUS:2AB), specifically focusing on its Enterprise Value to EBITDA forward metric. The platform indicates that the market is currently closed for this stock, with no trades r", "url": "https://www.tradingview.com/symbols/DUS-2AB/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:40:27", "published_display": "27 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRNS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a brief forecast for Barinthus Biotherapeutics plc (BRNS), indicating a consensus 1-year price target of $7.00 from one analyst. It also touches upon analyst ratings, EPS, and revenue metrics, noting that these are not investment advice.", "url": "https://www.tradingview.com/symbols/NASDAQ-BRNS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:44", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2AB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target for Barinthus Biotherapeutics plc Sponsored ADR (2AB) on the Frankfurt Stock Exchange, estimating it at 6.05. It notes that one analyst provided a one-year price forecast. The article also includes sections for analyst ratings, EPS, and revenu", "url": "https://www.tradingview.com/symbols/FWB-2AB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:11:40", "published_display": "25 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) Q1 2026 Earnings: Narrower Loss Beats Expectations, but Shares Slide", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNQUhGSWhIazJKZUxmLVM5UkZKSFNTZlk0ZjA2aVNEeDhwVnQxUC1RNHY4MEFWWVhOWkI4WkdkNmNwY1loN1JzbXVhZWtkckl1TUpVODFZLTkyMEtYc0xDbjZ6bVdfSGVoYWo0aE9mUldCSHNuVUgwRjhUS2F2ajVkNXd2R3hDeWRIT0tob2pFSFBqZlN6TWVxTXpnSFI3QVAwVktQLXZZNGI2MVRwRERPZG9FNU5WMm1DTGNya3Z6SU9lcG5tWGpyRHJVaTIwdmEtX1R1UER5UQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Barinthus Biotherapeutics PLC (BRNS), noting its current financial score of 6.82, which ranks it 201 out of 387 in the Biotechnology & Medical Research industry. While the company's financial status is robust, its operating eff", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/financial-health", "source_name": "TradingKey", "published_at": "2026-06-20T20:10:42", "published_display": "20 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Barinthus Biotherapeutics PLC (BRNS), listing its major individual and institutional holders. It also breaks down shareholder types, including venture capital, investment advisors, and individual investors, and provides quarterly ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T14:17:10", "published_display": "18 Jun 2026 14:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC", "summary": "This article provides an overview of Barinthus Biotherapeutics PLC (BRNS), a company listed on Nasdaq, including its current stock price and market capitalization. It highlights that relevant revenue breakdown data for the company by business segment and region has not yet been d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T04:09:04", "published_display": "18 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Barinthus Biotherapeutics PLC's (BRNS) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split events. The page also presents current stock pric", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T00:09:04", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Institutional Confidence", "summary": "Barinthus Biotherapeutics PLC (BRNS) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. Institutional shareholding decreased by 10.63% quarter-over-quarter, with the latest proportion at 40.87%. James Sim", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T16:39:27", "published_display": "17 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Barinthus Biotherapeutics PLC (BRNS) has an earnings forecast score of 8.00, placing it 163rd out of 388 in its industry. Analysts have set an average price target of $5.50 for BRNS, with a strong \"Buy\" trend based on the ratings of two analysts. The company's recent EPS was -$0.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T12:40:17", "published_display": "17 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Valuation: PE, PB & Fair Value Analysis", "summary": "Barinthus Biotherapeutics PLC (BRNS) has a current valuation score of 8.28, ranking 156 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.54, which is significantly below its recent high and above its recent low. Key valuation metrics like", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T15:40:17", "published_display": "16 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] Barinthus Biotherapeutics plc. SEC Filing", "summary": "This article announces an ARS SEC filing by Barinthus Biotherapeutics plc. (BRNS) on June 10, 2026. The filing is available as a PDF document through the SEC EDGAR system. The company's stock overview, market cap, and recent news and SEC filings are also provided.", "url": "https://www.stocktitan.net/sec-filings/BRNS/ars-barinthus-biotherapeutics-plc-sec-filing-3c557127c01b.html", "source_name": "Stock Titan", "published_at": "2026-06-11T01:09:17", "published_display": "11 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) schedules 2026 AGM with 7 key votes", "summary": "Barinthus Biotherapeutics (BRNS) has scheduled its 2026 Annual General Meeting for July 2, 2026, in London, where shareholders will vote on seven key proposals. These proposals include the re-election of two Class II directors, Karen T. Dawes and Anne M. Phillips, as well as the ", "url": "https://www.stocktitan.net/sec-filings/BRNS/def-14a-barinthus-biotherapeutics-plc-definitive-proxy-statement-e64bc813663d.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:09:17", "published_display": "10 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRNS - Barinthus Biotherapeutics Plc ADR Stock Price and Quote", "summary": "This article provides a detailed stock quote and financial overview for Barinthus Biotherapeutics Plc (BRNS), including its last close price, key financial metrics, various performance indicators, and recent news and analyst actions. The company is a clinical-stage biopharmaceuti", "url": "https://finviz.com/stock?t=BRNS", "source_name": "Finviz", "published_at": "2026-06-04T11:09:18", "published_display": "04 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) Edges Higher: Small Uptick in Low-Priced Stock - Volume Breakout Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOR3FHS0dCQl95b3VIUXhLVzNINFp4bmRuX043VEg4RWZxREJSbEpxMzIzbEpsNkI4T2lTUnNnTUtldnVyVlVzWnYzTzcxUVMxdV9LRFJUM1J1NXVUdmxhWGFxRjIxWXpta2ZSOUdYSHBSRmJIZGt6VlVFSU9uZTROWW5IV1dta1IxdGw3U0o4Z25saUtDeFNCeGE5bkxMcUp2YmRINi1ac3dha1l2WmxqbFFiQjFWR3NWTmc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics shareholders approve scheme of arrangement By Investing.com", "summary": "Barinthus Biotherapeutics shareholders have overwhelmingly approved a scheme of arrangement and related implementation proposal at recent meetings. The company's American Depositary Shares are listed on the Nasdaq Global Market under the symbol BRNS, and despite current trading a", "url": "https://za.investing.com/news/sec-filings/barinthus-biotherapeutics-shareholders-approve-scheme-of-arrangement-93CH-4293950", "source_name": "Investing.com South Africa", "published_at": "2026-05-22T06:09:08", "published_display": "22 May 2026 06:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics shareholders approve scheme of arrangement", "summary": "Barinthus Biotherapeutics shareholders have overwhelmingly approved a scheme of arrangement and related implementation proposals at recent meetings. The company, trading at $0.69 with a market cap of $28 million, received 99.98% support from voting shareholders despite being sign", "url": "https://m.uk.investing.com/news/sec-filings/barinthus-biotherapeutics-shareholders-approve-scheme-of-arrangement-93CH-4692291?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-21T12:10:18", "published_display": "21 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (NASDAQ: BRNS) investors back scheme implementation", "summary": "Barinthus Biotherapeutics' shareholders overwhelmingly approved a Scheme of Arrangement and related Scheme Implementation Proposal during recent court and general meetings. An impressive 99.98% of votes were cast in favor of the proposals at both meetings, ensuring a smooth path ", "url": "https://www.stocktitan.net/sec-filings/BRNS/8-k-barinthus-biotherapeutics-plc-reports-material-event-139d8081e14f.html", "source_name": "Stock Titan", "published_at": "2026-05-21T10:09:35", "published_display": "21 May 2026 10:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger between Barinthus Biotherapeutics plc (BRNS) and Clywedog Therapeutics, Inc. The law firm is examining whether the merger is fair to Barinthus shareholders, who will own only 34.33% of the combined company. KSF is ", "url": "https://www.businesswire.com/news/home/20260511755247/en/Barinthus-Biotherapeutics-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Merger-of-Barinthus-Biotherapeutics-plc---BRNS", "source_name": "Business Wire", "published_at": "2026-05-11T16:10:16", "published_display": "11 May 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRNS Stock Quote", "summary": "This page provides a stock quote for Barinthus Biotherapeutics PLC (BRNS) on TradingKey. It shows the current price of 0.685 USD, a 2.24% increase, and a market cap of 27.97M, reflecting its performance as of May 11, 16:00 ET. The page also features an overview of the company, fi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/comments", "source_name": "TradingKey", "published_at": "2026-05-11T14:10:16", "published_display": "11 May 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger between Barinthus Biotherapeutics plc (BRNS) and Clywedog Therapeutics, Inc. The investigation aims to determine if the merger terms are fair to Barinthus shareholders, who will own only 34.33% of the combined comp", "url": "https://markets.financialcontent.com/stocks/article/bizwire-2026-5-11-barinthus-biotherapeutics-investor-alert-kahn-swick-and-foti-llc-investigates-merger-of-barinthus-biotherapeutics-plc-brns?CSSURL=36.htm", "source_name": "FinancialContent", "published_at": "2026-05-11T12:08:00", "published_display": "11 May 2026 12:08", "sentiment": "negative", "sentiment_pct": 37, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Barinthus Biotherapeutics plc. 1Q 2026: Revenue ($8.37M), Net income ($5.53M), EPS ($0.14) \u2014 10-Q Summary", "summary": "Barinthus Biotherapeutics plc. reported its first-quarter 2026 results, showing a significant reduction in comprehensive and net loss compared to the previous year. The company is focusing its pipeline on immunology & inflammation, unwinding other programs, and plans an all-stock", "url": "https://www.tradingview.com/news/tradingview:fd7e7733b1d64:0-barinthus-biotherapeutics-plc-1q-2026-revenue-8-37m-net-income-5-53m-eps-0-14-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-05T00:10:16", "published_display": "05 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments", "summary": "Barinthus Bio reported its first quarter 2026 financial results, highlighting a progressing proposed combination with Clywedog Therapeutics Inc. that is expected to close mid-2026. The merged entity will focus on metabolic and autoimmune pipeline assets, including Barinthus Bio's", "url": "https://finance.yahoo.com/sectors/healthcare/articles/barinthus-bio-reports-first-quarter-113000290.html", "source_name": "Market source", "published_at": "2026-05-02T11:09:12", "published_display": "02 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC expected to post a loss of 28 cents a share - Earnings Preview", "summary": "Barinthus Biotherapeutics PLC (BRNS) is expected to announce an earnings loss of 28 cents per share. This information comes from a Reuters earnings preview. The article provides a brief outlook on the company's anticipated financial performance, indicating it will be reporting a ", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41E14G:0-barinthus-biotherapeutics-plc-expected-to-post-a-loss-of-28-cents-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-05-01T22:39:48", "published_display": "01 May 2026 22:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (NASDAQ: BRNS) files Form 3 for Principal Accounting Officer", "summary": "Barinthus Biotherapeutics (NASDAQ: BRNS) has filed a Form 3, an initial statement of beneficial ownership, for Douglas J. Swirsky, who has been appointed as the Principal Accounting Officer. This filing establishes his executive officer status but indicates no reportable share tr", "url": "https://www.stocktitan.net/sec-filings/BRNS/form-3-barinthus-biotherapeutics-plc-initial-statement-of-beneficial--7434740c4d41.html", "source_name": "Stock Titan", "published_at": "2026-05-01T20:09:29", "published_display": "01 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merger and trial plans shape Barinthus Bio (NASDAQ: BRNS) outlook", "summary": "Barinthus Bio reported a first-quarter 2026 net loss of $5.5 million, significantly improving from the prior year, driven by reduced operating expenses and a refocused portfolio. The company is advancing a proposed merger with Clywedog Therapeutics, expected to close mid-2026, wh", "url": "https://www.stocktitan.net/sec-filings/BRNS/8-k-barinthus-biotherapeutics-plc-reports-material-event-d174109ea2ac.html", "source_name": "Stock Titan", "published_at": "2026-04-30T11:38:37", "published_display": "30 Apr 2026 11:38", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNa3FUNFhuRk1LZERhNjV3Z1U0VERfTGN0LVM0ZXRLR1pYV243NmNzTHQxOXRUSTNySTBIQjB6OWpRY1F5d29YaTM1X1ZmMjBzMU5vOWtNcVpiZV9ENldzYW1VTXlGTWY3ZE9kYXZIS25obC1yVnJYMDNPN0piRjVfdGI2ZVpMNzBxLU9fQmx2SnVKNFJUQk85MmpzZF9ESHNKLTRmMWQ5YjB2a1ZxNVBfSksxdzZDNk5nYzZCVGRpU0E1elNsajNGb1g1Q0NJaXFXSmh5SE1IRQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-30T12:43:32+00:00", "published_display": "30 Sep 2025 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBGS1hIZVhZdzBfOUk5cU9lM2huYjdxUGlWY29qZEFlYXEzQkpIMk1mRmtVZTJtRTZJRlpaNHNkNWFncmx2ZmNHdGV0YmUzVy1OR2J3T1JJVGpNeklhSzhTNU5OUllKcnhuSXhIR2t0X21rMU0zNFhjUw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2024-08-03T19:28:29+00:00", "published_display": "03 Aug 2024 19:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1JNlB4WDJtRDBMR3FpYjExTUozRlBCZWgzY0k4SnljVkFiTTFncHBJRlJ5WjFKaFhOVE1qSDExdzZEY2ZUd0U5U1NTN25Od0VLTTFuamY4S1RJR3g3ZjA4ZzdnVzl4QQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:45:38+00:00", "published_display": "11 May 2024 13:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRNS Stock Price and Chart \u2014 NASDAQ:BRNS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBlclp6OWZlMTdrZjdEVWpOczhTU3JSbXdDMFAzd1I5Z1RoTWpUNy1EYkNNWlNUMDNJdXdITzFqUnQxc0dlWUwzcHdfNjRwVV9WRUFvMTRnVTByb2p4?oc=5", "source_name": "TradingView", "published_at": "2023-11-10T17:02:21+00:00", "published_display": "10 Nov 2023 17:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE4tN0xIMDE0SElBckt6dzJldHRLSTB0aDNuclEwV200SFNNbk9mczFBYjJlN1NZb0t2LVZjeVo2STFPb04zRHNRMy05MUJhc0QyQjZjV0NRSnU2UQ?oc=5", "source_name": "MarketBeat", "published_at": "2023-11-10T13:01:53+00:00", "published_display": "10 Nov 2023 13:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Barinthus Biotherapeutics (NasdaqCM:BRNS) Stock Price", "summary": "Barinthus Biotherapeutics (NasdaqCM:BRNS) has a market cap of US$26.1m and its stock price recently decreased by 36.22% over seven days. The company, founded in 2016, focuses on immunotherapies and vaccines, with candidates in clinical trials for celiac disease and chronic hepati", "url": "https://simplywall.st/stock/nasdaqcm/brns", "source_name": "Simply Wall Street", "published_at": "2026-07-05T01:10:43", "published_display": "05 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) wins more time to meet Nasdaq $1 bid rule", "summary": "Barinthus Biotherapeutics (BRNS) has been granted an additional 180 days, until December 28, 2026, by Nasdaq to regain compliance with the minimum $1.00 per share bid price requirement. In connection with this extension, its American Depositary Shares were transferred from the Na", "url": "https://www.stocktitan.net/sec-filings/BRNS/8-k-barinthus-biotherapeutics-plc-reports-material-event-b15c9c7d56b7.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:54", "published_display": "02 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) Sinks Further as Shares Test Critical Support Near $0.58 - Flat Correction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTUtHMTQtZ2J3alhFcVU0bENIY09iQjBkeHJEc0VQbTYwQTNDcGd4d0ppUUZVS2J2MnNnSXRyQy1xNjdXZlczRDdqeE0zc1N1M1F3aVRfQzRybXVaY3g2TEV2V1VLMGktUXlGRm1uZENsZDlCVjlxSllYNWtrcnA1NjZtTUlHWVVkeDBfWVc3d1BnTWlQZl9PRUJLOW8ySF8zRl9VMjlZcDZ6MnY0cm1sTXB2ckRrbHJIU2VUSldRMVY?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-02T16:33:41+00:00", "published_display": "02 Jul 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Barinthus Biotherapeutics plc \u2013 NASDAQ:BRNS", "summary": "This article provides the \"Price to book forward\" value for Barinthus Biotherapeutics plc (NASDAQ: BRNS) within the context of a financial data platform. It shows the company's stock market information and indicates that the market is currently closed with no trades. The article ", "url": "https://www.tradingview.com/symbols/NASDAQ-BRNS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T15:10:42", "published_display": "27 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Barinthus Biotherapeutics plc \u2013 NASDAQ:BRNS", "summary": "This article provides the \"Price to earnings forward\" financial data for Barinthus Biotherapeutics plc (NASDAQ:BRNS). It appears to be a direct data output from a financial platform, showing the value and change percentages for this specific metric, though the values themselves a", "url": "https://www.tradingview.com/symbols/NASDAQ-BRNS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:27", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Barinthus Biotherapeutics plc Sponsored ADR \u2013 DUS:2AB", "summary": "This page from TradingView provides financial information for Barinthus Biotherapeutics plc Sponsored ADR (DUS:2AB), specifically focusing on its Enterprise Value to EBITDA forward metric. The platform indicates that the market is currently closed for this stock, with no trades r", "url": "https://www.tradingview.com/symbols/DUS-2AB/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:40:27", "published_display": "27 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRNS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a brief forecast for Barinthus Biotherapeutics plc (BRNS), indicating a consensus 1-year price target of $7.00 from one analyst. It also touches upon analyst ratings, EPS, and revenue metrics, noting that these are not investment advice.", "url": "https://www.tradingview.com/symbols/NASDAQ-BRNS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:44", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2AB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target for Barinthus Biotherapeutics plc Sponsored ADR (2AB) on the Frankfurt Stock Exchange, estimating it at 6.05. It notes that one analyst provided a one-year price forecast. The article also includes sections for analyst ratings, EPS, and revenu", "url": "https://www.tradingview.com/symbols/FWB-2AB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:11:40", "published_display": "25 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) Q1 2026 Earnings: Narrower Loss Beats Expectations, but Shares Slide", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNQUhGSWhIazJKZUxmLVM5UkZKSFNTZlk0ZjA2aVNEeDhwVnQxUC1RNHY4MEFWWVhOWkI4WkdkNmNwY1loN1JzbXVhZWtkckl1TUpVODFZLTkyMEtYc0xDbjZ6bVdfSGVoYWo0aE9mUldCSHNuVUgwRjhUS2F2ajVkNXd2R3hDeWRIT0tob2pFSFBqZlN6TWVxTXpnSFI3QVAwVktQLXZZNGI2MVRwRERPZG9FNU5WMm1DTGNya3Z6SU9lcG5tWGpyRHJVaTIwdmEtX1R1UER5UQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Barinthus Biotherapeutics PLC (BRNS), noting its current financial score of 6.82, which ranks it 201 out of 387 in the Biotechnology & Medical Research industry. While the company's financial status is robust, its operating eff", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/financial-health", "source_name": "TradingKey", "published_at": "2026-06-20T20:10:42", "published_display": "20 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Barinthus Biotherapeutics PLC (BRNS), listing its major individual and institutional holders. It also breaks down shareholder types, including venture capital, investment advisors, and individual investors, and provides quarterly ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T14:17:10", "published_display": "18 Jun 2026 14:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC", "summary": "This article provides an overview of Barinthus Biotherapeutics PLC (BRNS), a company listed on Nasdaq, including its current stock price and market capitalization. It highlights that relevant revenue breakdown data for the company by business segment and region has not yet been d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T04:09:04", "published_display": "18 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Barinthus Biotherapeutics PLC's (BRNS) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split events. The page also presents current stock pric", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T00:09:04", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Institutional Confidence", "summary": "Barinthus Biotherapeutics PLC (BRNS) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. Institutional shareholding decreased by 10.63% quarter-over-quarter, with the latest proportion at 40.87%. James Sim", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T16:39:27", "published_display": "17 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Barinthus Biotherapeutics PLC (BRNS) has an earnings forecast score of 8.00, placing it 163rd out of 388 in its industry. Analysts have set an average price target of $5.50 for BRNS, with a strong \"Buy\" trend based on the ratings of two analysts. The company's recent EPS was -$0.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T12:40:17", "published_display": "17 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC (BRNS) Valuation: PE, PB & Fair Value Analysis", "summary": "Barinthus Biotherapeutics PLC (BRNS) has a current valuation score of 8.28, ranking 156 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.54, which is significantly below its recent high and above its recent low. Key valuation metrics like", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T15:40:17", "published_display": "16 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] Barinthus Biotherapeutics plc. SEC Filing", "summary": "This article announces an ARS SEC filing by Barinthus Biotherapeutics plc. (BRNS) on June 10, 2026. The filing is available as a PDF document through the SEC EDGAR system. The company's stock overview, market cap, and recent news and SEC filings are also provided.", "url": "https://www.stocktitan.net/sec-filings/BRNS/ars-barinthus-biotherapeutics-plc-sec-filing-3c557127c01b.html", "source_name": "Stock Titan", "published_at": "2026-06-11T01:09:17", "published_display": "11 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) schedules 2026 AGM with 7 key votes", "summary": "Barinthus Biotherapeutics (BRNS) has scheduled its 2026 Annual General Meeting for July 2, 2026, in London, where shareholders will vote on seven key proposals. These proposals include the re-election of two Class II directors, Karen T. Dawes and Anne M. Phillips, as well as the ", "url": "https://www.stocktitan.net/sec-filings/BRNS/def-14a-barinthus-biotherapeutics-plc-definitive-proxy-statement-e64bc813663d.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:09:17", "published_display": "10 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRNS - Barinthus Biotherapeutics Plc ADR Stock Price and Quote", "summary": "This article provides a detailed stock quote and financial overview for Barinthus Biotherapeutics Plc (BRNS), including its last close price, key financial metrics, various performance indicators, and recent news and analyst actions. The company is a clinical-stage biopharmaceuti", "url": "https://finviz.com/stock?t=BRNS", "source_name": "Finviz", "published_at": "2026-06-04T11:09:18", "published_display": "04 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) Edges Higher: Small Uptick in Low-Priced Stock - Volume Breakout Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOR3FHS0dCQl95b3VIUXhLVzNINFp4bmRuX043VEg4RWZxREJSbEpxMzIzbEpsNkI4T2lTUnNnTUtldnVyVlVzWnYzTzcxUVMxdV9LRFJUM1J1NXVUdmxhWGFxRjIxWXpta2ZSOUdYSHBSRmJIZGt6VlVFSU9uZTROWW5IV1dta1IxdGw3U0o4Z25saUtDeFNCeGE5bkxMcUp2YmRINi1ac3dha1l2WmxqbFFiQjFWR3NWTmc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics shareholders approve scheme of arrangement By Investing.com", "summary": "Barinthus Biotherapeutics shareholders have overwhelmingly approved a scheme of arrangement and related implementation proposal at recent meetings. The company's American Depositary Shares are listed on the Nasdaq Global Market under the symbol BRNS, and despite current trading a", "url": "https://za.investing.com/news/sec-filings/barinthus-biotherapeutics-shareholders-approve-scheme-of-arrangement-93CH-4293950", "source_name": "Investing.com South Africa", "published_at": "2026-05-22T06:09:08", "published_display": "22 May 2026 06:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics shareholders approve scheme of arrangement", "summary": "Barinthus Biotherapeutics shareholders have overwhelmingly approved a scheme of arrangement and related implementation proposals at recent meetings. The company, trading at $0.69 with a market cap of $28 million, received 99.98% support from voting shareholders despite being sign", "url": "https://m.uk.investing.com/news/sec-filings/barinthus-biotherapeutics-shareholders-approve-scheme-of-arrangement-93CH-4692291?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-21T12:10:18", "published_display": "21 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (NASDAQ: BRNS) investors back scheme implementation", "summary": "Barinthus Biotherapeutics' shareholders overwhelmingly approved a Scheme of Arrangement and related Scheme Implementation Proposal during recent court and general meetings. An impressive 99.98% of votes were cast in favor of the proposals at both meetings, ensuring a smooth path ", "url": "https://www.stocktitan.net/sec-filings/BRNS/8-k-barinthus-biotherapeutics-plc-reports-material-event-139d8081e14f.html", "source_name": "Stock Titan", "published_at": "2026-05-21T10:09:35", "published_display": "21 May 2026 10:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger between Barinthus Biotherapeutics plc (BRNS) and Clywedog Therapeutics, Inc. The law firm is examining whether the merger is fair to Barinthus shareholders, who will own only 34.33% of the combined company. KSF is ", "url": "https://www.businesswire.com/news/home/20260511755247/en/Barinthus-Biotherapeutics-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Merger-of-Barinthus-Biotherapeutics-plc---BRNS", "source_name": "Business Wire", "published_at": "2026-05-11T16:10:16", "published_display": "11 May 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRNS Stock Quote", "summary": "This page provides a stock quote for Barinthus Biotherapeutics PLC (BRNS) on TradingKey. It shows the current price of 0.685 USD, a 2.24% increase, and a market cap of 27.97M, reflecting its performance as of May 11, 16:00 ET. The page also features an overview of the company, fi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brns/comments", "source_name": "TradingKey", "published_at": "2026-05-11T14:10:16", "published_display": "11 May 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger between Barinthus Biotherapeutics plc (BRNS) and Clywedog Therapeutics, Inc. The investigation aims to determine if the merger terms are fair to Barinthus shareholders, who will own only 34.33% of the combined comp", "url": "https://markets.financialcontent.com/stocks/article/bizwire-2026-5-11-barinthus-biotherapeutics-investor-alert-kahn-swick-and-foti-llc-investigates-merger-of-barinthus-biotherapeutics-plc-brns?CSSURL=36.htm", "source_name": "FinancialContent", "published_at": "2026-05-11T12:08:00", "published_display": "11 May 2026 12:08", "sentiment": "negative", "sentiment_pct": 37, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics plc. 1Q 2026: Revenue ($8.37M), Net income ($5.53M), EPS ($0.14) \u2014 10-Q Summary", "summary": "Barinthus Biotherapeutics plc. reported its first-quarter 2026 results, showing a significant reduction in comprehensive and net loss compared to the previous year. The company is focusing its pipeline on immunology & inflammation, unwinding other programs, and plans an all-stock", "url": "https://www.tradingview.com/news/tradingview:fd7e7733b1d64:0-barinthus-biotherapeutics-plc-1q-2026-revenue-8-37m-net-income-5-53m-eps-0-14-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-05T00:10:16", "published_display": "05 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments", "summary": "Barinthus Bio reported its first quarter 2026 financial results, highlighting a progressing proposed combination with Clywedog Therapeutics Inc. that is expected to close mid-2026. The merged entity will focus on metabolic and autoimmune pipeline assets, including Barinthus Bio's", "url": "https://finance.yahoo.com/sectors/healthcare/articles/barinthus-bio-reports-first-quarter-113000290.html", "source_name": "Market source", "published_at": "2026-05-02T11:09:12", "published_display": "02 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics PLC expected to post a loss of 28 cents a share - Earnings Preview", "summary": "Barinthus Biotherapeutics PLC (BRNS) is expected to announce an earnings loss of 28 cents per share. This information comes from a Reuters earnings preview. The article provides a brief outlook on the company's anticipated financial performance, indicating it will be reporting a ", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41E14G:0-barinthus-biotherapeutics-plc-expected-to-post-a-loss-of-28-cents-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-05-01T22:39:48", "published_display": "01 May 2026 22:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (NASDAQ: BRNS) files Form 3 for Principal Accounting Officer", "summary": "Barinthus Biotherapeutics (NASDAQ: BRNS) has filed a Form 3, an initial statement of beneficial ownership, for Douglas J. Swirsky, who has been appointed as the Principal Accounting Officer. This filing establishes his executive officer status but indicates no reportable share tr", "url": "https://www.stocktitan.net/sec-filings/BRNS/form-3-barinthus-biotherapeutics-plc-initial-statement-of-beneficial--7434740c4d41.html", "source_name": "Stock Titan", "published_at": "2026-05-01T20:09:29", "published_display": "01 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merger and trial plans shape Barinthus Bio (NASDAQ: BRNS) outlook", "summary": "Barinthus Bio reported a first-quarter 2026 net loss of $5.5 million, significantly improving from the prior year, driven by reduced operating expenses and a refocused portfolio. The company is advancing a proposed merger with Clywedog Therapeutics, expected to close mid-2026, wh", "url": "https://www.stocktitan.net/sec-filings/BRNS/8-k-barinthus-biotherapeutics-plc-reports-material-event-d174109ea2ac.html", "source_name": "Stock Titan", "published_at": "2026-04-30T11:38:37", "published_display": "30 Apr 2026 11:38", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNa3FUNFhuRk1LZERhNjV3Z1U0VERfTGN0LVM0ZXRLR1pYV243NmNzTHQxOXRUSTNySTBIQjB6OWpRY1F5d29YaTM1X1ZmMjBzMU5vOWtNcVpiZV9ENldzYW1VTXlGTWY3ZE9kYXZIS25obC1yVnJYMDNPN0piRjVfdGI2ZVpMNzBxLU9fQmx2SnVKNFJUQk85MmpzZF9ESHNKLTRmMWQ5YjB2a1ZxNVBfSksxdzZDNk5nYzZCVGRpU0E1elNsajNGb1g1Q0NJaXFXSmh5SE1IRQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-30T12:43:32+00:00", "published_display": "30 Sep 2025 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBGS1hIZVhZdzBfOUk5cU9lM2huYjdxUGlWY29qZEFlYXEzQkpIMk1mRmtVZTJtRTZJRlpaNHNkNWFncmx2ZmNHdGV0YmUzVy1OR2J3T1JJVGpNeklhSzhTNU5OUllKcnhuSXhIR2t0X21rMU0zNFhjUw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2024-08-03T19:28:29+00:00", "published_display": "03 Aug 2024 19:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1JNlB4WDJtRDBMR3FpYjExTUozRlBCZWgzY0k4SnljVkFiTTFncHBJRlJ5WjFKaFhOVE1qSDExdzZEY2ZUd0U5U1NTN25Od0VLTTFuamY4S1RJR3g3ZjA4ZzdnVzl4QQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:45:38+00:00", "published_display": "11 May 2024 13:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRNS Stock Price and Chart \u2014 NASDAQ:BRNS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBlclp6OWZlMTdrZjdEVWpOczhTU3JSbXdDMFAzd1I5Z1RoTWpUNy1EYkNNWlNUMDNJdXdITzFqUnQxc0dlWUwzcHdfNjRwVV9WRUFvMTRnVTByb2p4?oc=5", "source_name": "TradingView", "published_at": "2023-11-10T17:02:21+00:00", "published_display": "10 Nov 2023 17:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE4tN0xIMDE0SElBckt6dzJldHRLSTB0aDNuclEwV200SFNNbk9mczFBYjJlN1NZb0t2LVZjeVo2STFPb04zRHNRMy05MUJhc0QyQjZjV0NRSnU2UQ?oc=5", "source_name": "MarketBeat", "published_at": "2023-11-10T13:01:53+00:00", "published_display": "10 Nov 2023 13:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 44, "sentiment_summary": {"positive": 8, "negative": 5, "neutral": 31, "score": 51, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 0.56, "latest_week": "2026-07-17", "one_week_move": -12.9, "four_week_move": -16.1, "twelve_week_move": -13.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.634238, "market_dynamics_buy_signal": false, "relative_strength": -42.78748, "fair_value_gap": -63.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.6744, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-12.9% over one week, -16.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 8}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "dars.gov.et", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "Simply Wall Street", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-12.9% over one week, -16.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Barinthus Biotherapeutics (NasdaqCM:BRNS) Stock Price"}], "updated_at": "2026-07-18T11:00:53.907758+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}